Seattle Genetics was founded in 1998, and since then, its focus has always been the study, manipulation, and packaging of drugs. Seattle Genetics is a Biotechnology Company which focuses on the development and commercialization of innovative antibody-based therapies for cancer treatment. The main focus of Seattle Genetics is an antibody-drug conjugate which targets antigens protein molecules which causes the immune system to produce antibodies. The drugs attach on the outside of cancer cells in Hodgkin Lymphoma and deliver toxin inside the cells to kill them. This reduces the collateral damage on the healthy cells during radiation and traditional chemotherapy.
The first drug produced by the company to be approved was Adcetris which is used when patients do not get enough response from the first and second drugs intake. If researchers confirm that Adcetris compares favorably to the front-line therapy, it would become the first drug by choice of oncologists for the diagnosis. The designated sales years would give back an estimated return as high as $1 billion.
According to Adam Feuerstein, Adcetris has been relatively successful but is not yet a blockbuster. The other strategy used by the firm is the study of Adcetris as a blended treatment with one of the most recent immunotherapies known as Opdivo which works as a checkpoint inhibitor. The Echelon 1 study compares the drug to the standard treatment for newly diagnosed patients. The results of the study which are expected this year could assure the oncologists in the country to accept Adcetris as a principal therapy if they show a dramatic result.
Despite the confusing political and economic climate, Siegall remains philosophical and steadfast. He admits that he loves making drugs, but it is not an easy thing to do. He works hard to ensure that he completely focuses on his work. Early in his career, he admired and imitated the moves which he saw Art Levinson making with biotech Genentech and today, he is the chairman of Apple Inc and is admired by many people. Dr. Clay Siegall attributes his success to not giving up.
Dr. Clay Siegall is the co-founder of Seattle Genetics. He is the president and chief executive officer of the company. He is also the chairman of the Board of the company. Dr. Clay Siegall worked at the Bristol Myers Squibb Pharmaceutical Research Institute from 1991 to 1997, and he served at the National Cancer Institute from 1991 to 1997. Dr. Clay Siegall is also the Director of Alder Biopharmaceuticals, Inc.